BRISTOL-MYERS SQUIBBDL-10
BRISTOL-MYERS SQUIBBDL-10/ US1101221083 /
BRM
10/18/2024 1:02:58 PM
|
Chg.
-0.190
|
Volume |
Bid1:37:45 PM |
Ask1:37:45 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
49.055EUR
|
-0.39%
|
452 Turnover: 22,201.980 |
49.005Bid Size: 62 |
49.250Ask Size: 250 |
99.54 bill.EUR |
- |
- |
Business description
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Management board & Supervisory board
CEO |
Giovanni Caforio |
Management board |
David Elkins, Chris Boerner, Pamela Fisher, Cari Gallman, Samit Hirawat, Adam Lenkowsky, Sandra Leung, Greg Meyers, Elizabeth A. Mily, Peter S. Paine III, Robert Plenge, Ann M. Powell, Karin Shanahan, Estelle Vester-Blokland |
Supervisory board |
Giovanni Caforio, Derica W. Rice, Dr. Karen H. Vousden, Julia A. Haller, Manuel Hidalgo Medina, Paula A. Price, Peter J. Arduini, Phyllis Yale, Theodore R. Samuels, Gerald L. Storch, Chris Boerner, Deepak L. Bhatt |
Company data
Name: |
Bristol-Myers Squibb Co. |
Address: |
430 E. 29th Street, 14FL,New York, New York 10016 USA |
Phone: |
+1-212-546-4000 |
Fax: |
+1-212-546-4020 |
E-mail: |
-
|
Internet: |
www.bms.com |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12/31 |
Free Float: |
- |
IPO date: |
1/3/1972 |
Company calendar
CW 44 | 10/31/2024
Interim Report 3rd Quarter/9 Months
|
CW 44 | 11/1/2024
Dividend Payment
|